Assessment of clonality in gastrointestinal cancer by DNA fingerprinting.

M F Fey; R A Wells; J S Wainscoat; S L Thein

doi:10.1172/JCI113762

Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.

Find articles by Fey, M. in: PubMed | Google Scholar

Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.

Find articles by Wells, R. in: PubMed | Google Scholar

Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.

Find articles by Wainscoat, J. in: PubMed | Google Scholar

Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.

Find articles by Thein, S. in: PubMed | Google Scholar

Published in Volume 82, Issue 5 on November 1, 1988
J Clin Invest. 1988;82(5):1532–1537. https://doi.org/10.1172/JCI113762.
© 1988 The American Society for Clinical Investigation

Published November 1, 1988 - Version history

DNA fingerprinting with three different probes (33.15, 33.6, and alpha-globin 3'HVR) was investigated as a method for the determination of clonality in gastrointestinal tumors. In 29/44 carcinomas the tumor DNA showed clonal somatic mutations that were not seen in the corresponding peripheral blood and normal mucosa samples. The changes consisted of either novel fingerprint bands, losses of bands, or both. The probe 33.15 yielded the highest rate of abnormal DNA fingerprints (21/44 carcinomas). Sequential use of the probes increased the number of cases where clonal fingerprint markers could be detected. One out of five colorectal adenomas also showed a clonal loss of a fingerprint band. In two cases of gastric cancer, DNA from the metastatic tumor had a different DNA fingerprint from that found in the primary carcinoma. DNA fingerprinting offers a novel approach to determining clonality in tumors and may prove useful for the study of tumor progression.

Images.